Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of decitabine in chronic myelomonocytic leukemia
2008-000470-21Phase 2Active
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine in chronic myelomonocytic leukemia (CMML), sponsored by Groupe Français des Myélodysplasies. Primary endpoints: Hematological response rate at three cycles, Hematological response rate at six cycles and 1 more. Started May 2008; status: active.
02
Drugs
decitabine
03
Conditions
chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on 2008-000470-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000470-21.